Anne Sae Lim von Stuckrad
Research Subjects
Anne Sae Lim von Stuckrad has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Tilmann Kallinich
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Augustenburger Platz, Berlin, 13353, Germany.
5 shared publications - Mir-Farzin Mashreghi
German Rheumatology Research Center, a Leibniz-Institute (DRFZ), Berlin, Germany
2 shared publications Nadine Unterwalder
Institute for Medical Immunology, Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany
2 shared publications- Philipp Enghard
Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2 shared publications - Robert Biesen
Department of Rheumatology and Clinical Immunology, Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2 shared publications - Adam P. Croft
Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK
1 shared publication
Latest Publications
- Open Access
Tissue-adapted NK cells shape pathogenic cDC1 niches in early arthritis
Chronic forms of autoimmune arthritis, including juvenile idiopathic arthritis (JIA), are characterised by persistent synovial inflammation. While adaptive mechanisms are well-studied, the innate networks driving early joint disease remain poorly defined. Here, through unbiased profiling of innate lymphoid cells from the joints of children with JIA at disease onset, we identify activated natural killer (NK) cells as key orchestrators of adaptive immune niches. The selective upregulation of lymphotactin (XCL1) by activated NK cells is accompanied by the synovial enrichment of XCR1 + type 1 conventional dendritic cells (cDC1s), directly correlating with disease severity. In situ, NK cells spatially anchor with recruited cDC1s to assemble discrete, multicellular effector niches alongside T cells. Finally, we demonstrate this NK-cDC1 spatial architecture represents a conserved pathogenic module across adult arthropathies, including rheumatoid arthritis. Our findings establish the XCL1-XCR1 axis as a fundamental innate feature of chronic joint inflammation, defining a targetable mechanism that precedes and promotes downstream adaptive responses.
Open AccessTissue-adapted NK cells shape pathogenic cDC1 niches in early arthritis
Chronic forms of autoimmune arthritis, including juvenile idiopathic arthritis (JIA), are characterised by persistent synovial inflammation. While adaptive mechanisms are well-studied, the innate networks driving early joint disease remain poorly defined. Here, through unbiased profiling of innate lymphoid cells from the joints of children with JIA at disease onset, we identify activated natural killer (NK) cells as key orchestrators of adaptive immune niches. The selective upregulation of lymphotactin (XCL1) by activated NK cells is accompanied by the synovial enrichment of XCR1 + type 1 conventional dendritic cells (cDC1s), directly correlating with disease severity. In situ, NK cells spatially anchor with recruited cDC1s to assemble discrete, multicellular effector niches alongside T cells. Finally, we demonstrate this NK-cDC1 spatial architecture represents a conserved pathogenic module across adult arthropathies, including rheumatoid arthritis. Our findings establish the XCL1-XCR1 axis as a fundamental innate feature of chronic joint inflammation, defining a targetable mechanism that precedes and promotes downstream adaptive responses.
- 3 November 2023
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 83 (1) , 4-14
Monogenic variants in Laccase domain-containing 1 (LACC1) as the cause of juvenile arthritis
Zusammenfassung Monogene Mutationen in „laccase domain-containing 1“ (LACC1) sind mit Krankheitsbildern assoziiert, die schweren Verläufen einer polyartikulären oder systemischen juvenilen idiopathischen Arthritis entsprechen. Die Erkrankungen zeichnen sich durch einen Beginn während der ersten Lebensjahre, eine familiäre Häufung sowie eine hohe Entzündungsaktivität aus. Die Verläufe sind meist schwer therapeutisch zu beeinflussen und führen häufig zu Folgeschäden. Vorgestellt werden vier Fälle aus zwei Familien, bei denen die homozygote Mutation p.T276fs* in LACC1 nachgewiesen wurde. Die Kinder litten initial an polyartikulären bzw. systemischen Formen einer juvenilen Arthritis. Zwei Patienten werden derzeit mit Tocilizumab und Methotrexat behandelt, eine Patientin ohne Basistherapie wird aktuell nur durch lokale wiederholte intraartikuläre Steroide therapiert. Bei der vierten Patientin wurde aufgrund eines Rezidivs einer akuten lymphatischen Leukämie eine allogene Knochenmarktransplantation durchgeführt. Seither traten keine weiteren entzündlichen Symptome auf. Die vorgestellten Fälle werden mit den weiteren 50 bisher publizierten Verläufen verglichen. Zudem werden aktuelle Arbeiten, die den Einfluss der LACC1-Mutationen insbesondere auf die Funktion der Makrophagen untersuchten, zusammengefasst.
- 3 November 2023
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 83 (1) , 4-14
Monogenic variants in Laccase domain-containing 1 (LACC1) as the cause of juvenile arthritis
Zusammenfassung Monogene Mutationen in „laccase domain-containing 1“ (LACC1) sind mit Krankheitsbildern assoziiert, die schweren Verläufen einer polyartikulären oder systemischen juvenilen idiopathischen Arthritis entsprechen. Die Erkrankungen zeichnen sich durch einen Beginn während der ersten Lebensjahre, eine familiäre Häufung sowie eine hohe Entzündungsaktivität aus. Die Verläufe sind meist schwer therapeutisch zu beeinflussen und führen häufig zu Folgeschäden. Vorgestellt werden vier Fälle aus zwei Familien, bei denen die homozygote Mutation p.T276fs* in LACC1 nachgewiesen wurde. Die Kinder litten initial an polyartikulären bzw. systemischen Formen einer juvenilen Arthritis. Zwei Patienten werden derzeit mit Tocilizumab und Methotrexat behandelt, eine Patientin ohne Basistherapie wird aktuell nur durch lokale wiederholte intraartikuläre Steroide therapiert. Bei der vierten Patientin wurde aufgrund eines Rezidivs einer akuten lymphatischen Leukämie eine allogene Knochenmarktransplantation durchgeführt. Seither traten keine weiteren entzündlichen Symptome auf. Die vorgestellten Fälle werden mit den weiteren 50 bisher publizierten Verläufen verglichen. Zudem werden aktuelle Arbeiten, die den Einfluss der LACC1-Mutationen insbesondere auf die Funktion der Makrophagen untersuchten, zusammengefasst.
- 8 June 2022
- Published by Springer Nature
- p. 279-290
Gelenkpunktionen in der pädiatrischen Rheumatologie
- 8 June 2022
- Published by Springer Nature
- p. 279-290
Gelenkpunktionen in der pädiatrischen Rheumatologie
- 30 November 2021
- Published by Springer Nature
- p. 1-12
Gelenkpunktionen in der pädiatrischen Rheumatologie
- 30 November 2021
- Published by Springer Nature
- p. 1-12
Gelenkpunktionen in der pädiatrischen Rheumatologie
- Open Access
Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus
Objectives: To evaluate and compare the diagnostic accuracy of SIGLEC1, a surrogate marker of type I IFN, with established biomarkers in an inception cohort of systemic lupus erythematosus (SLE). Methods: SIGLEC1 was analysed by flow cytometry in 232 patients referred to our institution with suspected SLE between October 2015 and September 2020. Results: SLE was confirmed in 76 of 232 patients (32.8%) according to the 2019 EULAR/ACR classification criteria and their SIGLEC1 values were significantly higher compared to patients without SLE (p 99.9 % and 0.1 %, respectively. Using ROC analysis and Delong testing, the area under the curve (AUC) for SIGLEC1 (AUC=0.95) was significantly higher than for ANA (AUC=0.88, p=0.031), C3 (AUC=0.83, p=0.001) and C4 (AUC=0.83, p=0.002) but not for anti-dsDNA antibodies (AUC=0.90, p=0.163). Conclusion: IFN-I pathway activation is detectable in almost all newly diagnosed SLE patients. Thus, a negative test result for SIGLEC1 is powerful to exclude SLE in suspected cases.
Open AccessEvaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus
Objectives: To evaluate and compare the diagnostic accuracy of SIGLEC1, a surrogate marker of type I IFN, with established biomarkers in an inception cohort of systemic lupus erythematosus (SLE). Methods: SIGLEC1 was analysed by flow cytometry in 232 patients referred to our institution with suspected SLE between October 2015 and September 2020. Results: SLE was confirmed in 76 of 232 patients (32.8%) according to the 2019 EULAR/ACR classification criteria and their SIGLEC1 values were significantly higher compared to patients without SLE (p 99.9 % and 0.1 %, respectively. Using ROC analysis and Delong testing, the area under the curve (AUC) for SIGLEC1 (AUC=0.95) was significantly higher than for ANA (AUC=0.88, p=0.031), C3 (AUC=0.83, p=0.001) and C4 (AUC=0.83, p=0.002) but not for anti-dsDNA antibodies (AUC=0.90, p=0.163). Conclusion: IFN-I pathway activation is detectable in almost all newly diagnosed SLE patients. Thus, a negative test result for SIGLEC1 is powerful to exclude SLE in suspected cases.
- Open Access
- 20 October 2020
- Published by SAGE Publications in Lupus
- Vol. 29 (14) , 1914-1925
SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus
Background: To analyse the validity of membrane-bound SIGLEC1 (CD169) as a sensitive biomarker for monitoring disease activity in pediatric systemic lupus erythematosus (SLE). Methods: 27 children and adolescents with SLE were followed for a mean of 13.5 months. During consecutive routine visits SLEDAI-2k, C3, C4 and ds-DNA values were determined. Additionally, expression of SIGLEC1 on monocytes was determined by flow cytometry. The amount of PE-labelled CD169 mAb bound per monocyte was analyzed using QuantiBRITE™ PE tubes. Associations between biomarkers and the clinical course were investigated by regression analysis. Results: In general, SIGLEC1 expression is high on SLE-derived monocytes (mean 6 359 (SD 6 056) molecules/monocyte, cut-off 2 500 molecules/monocyte), all patients with newly diagnosed SLE exhibit elevated expression (mean 13366 (SD 7 750) molecules/monocyte). Changes (Δ) in SIGLEC1 levels during the clinical course is the only biomarker that significantly correlates with the change in SLEDAI-2k (betaST = 0.28, p = 0.001). At follow-up visit, a clinically important worsening was experienced by 47.6% of patients with a Δ SIGLEC1 > 2 151 molecules/cell (OR 5.31) and 72.4% with a Δ SIGLEC1 > 756 molecules/cell (OR 8.90). Conversely, 36.4% of patients with a Δ SIGLEC1 < -2 818 molecules/cell (OR 4.16, percentiles as cut-off criteria) and 50.0% of patients with a Δ SIGLEC1 < -1 370 molecules/cell (OR 3.55, application of Youden index) showed clinical improvement. SIGLEC1 expression correlates inversely with the amount of therapeutically applied hydroxychloroquine (p < 0.001). Conclusions: SIGLEC1 expression on monocytes is a sensitive biomarker for adjusting disease activity in childhood SLE and represents a promising and easily applicable tool for disease monitoring.
- 20 October 2020
- Published by SAGE Publications in Lupus
- Vol. 29 (14) , 1914-1925
Open AccessSIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus
Background: To analyse the validity of membrane-bound SIGLEC1 (CD169) as a sensitive biomarker for monitoring disease activity in pediatric systemic lupus erythematosus (SLE). Methods: 27 children and adolescents with SLE were followed for a mean of 13.5 months. During consecutive routine visits SLEDAI-2k, C3, C4 and ds-DNA values were determined. Additionally, expression of SIGLEC1 on monocytes was determined by flow cytometry. The amount of PE-labelled CD169 mAb bound per monocyte was analyzed using QuantiBRITE™ PE tubes. Associations between biomarkers and the clinical course were investigated by regression analysis. Results: In general, SIGLEC1 expression is high on SLE-derived monocytes (mean 6 359 (SD 6 056) molecules/monocyte, cut-off 2 500 molecules/monocyte), all patients with newly diagnosed SLE exhibit elevated expression (mean 13366 (SD 7 750) molecules/monocyte). Changes (Δ) in SIGLEC1 levels during the clinical course is the only biomarker that significantly correlates with the change in SLEDAI-2k (betaST = 0.28, p = 0.001). At follow-up visit, a clinically important worsening was experienced by 47.6% of patients with a Δ SIGLEC1 > 2 151 molecules/cell (OR 5.31) and 72.4% with a Δ SIGLEC1 > 756 molecules/cell (OR 8.90). Conversely, 36.4% of patients with a Δ SIGLEC1 < -2 818 molecules/cell (OR 4.16, percentiles as cut-off criteria) and 50.0% of patients with a Δ SIGLEC1 < -1 370 molecules/cell (OR 3.55, application of Youden index) showed clinical improvement. SIGLEC1 expression correlates inversely with the amount of therapeutically applied hydroxychloroquine (p < 0.001). Conclusions: SIGLEC1 expression on monocytes is a sensitive biomarker for adjusting disease activity in childhood SLE and represents a promising and easily applicable tool for disease monitoring.
- Open Access
Antigen-driven PD-1 + TOX + EOMES + and PD-1 + TOX + BHLHE40 + synovial T lymphocytes regulate chronic inflammation in situ
Introduction/ T lymphocytes accumulate in inflamed tissues of patients with chronic inflammatory diseases (CIDs) and express pro-inflammatory cytokines upon re-stimulation in vitro 1–29 . Further, a significant genetic linkage to MHC genes suggests that T lymphocytes play an important role in the pathogenesis of CIDs including juvenile idiopathic arthritis (JIA) 30–33 . However, the functions of T lymphocytes in established disease remain elusive. Here we dissect the heterogeneity of synovial T lymphocytes in JIA patients by single cell RNA-sequencing. We identify subpopulations of T lymphocytes expressing genes reflecting recent activation by antigen in situ . A PD-1 + TOX + EOMES + population of CD4 + T lymphocytes expressed immune regulatory genes and chemoattractant genes for myeloid cells. A PD-1 + TOX + BHLHE40 + population of CD4 + , and a mirror population of CD8 + T lymphocytes expressed genes driving inflammation, and genes supporting B lymphocyte activation. This analysis points out that multiple types of T lymphocytes have to be targeted for therapeutic regeneration of tolerance in arthritis.
Open AccessAntigen-driven PD-1 + TOX + EOMES + and PD-1 + TOX + BHLHE40 + synovial T lymphocytes regulate chronic inflammation in situ
Introduction/ T lymphocytes accumulate in inflamed tissues of patients with chronic inflammatory diseases (CIDs) and express pro-inflammatory cytokines upon re-stimulation in vitro 1–29 . Further, a significant genetic linkage to MHC genes suggests that T lymphocytes play an important role in the pathogenesis of CIDs including juvenile idiopathic arthritis (JIA) 30–33 . However, the functions of T lymphocytes in established disease remain elusive. Here we dissect the heterogeneity of synovial T lymphocytes in JIA patients by single cell RNA-sequencing. We identify subpopulations of T lymphocytes expressing genes reflecting recent activation by antigen in situ . A PD-1 + TOX + EOMES + population of CD4 + T lymphocytes expressed immune regulatory genes and chemoattractant genes for myeloid cells. A PD-1 + TOX + BHLHE40 + population of CD4 + , and a mirror population of CD8 + T lymphocytes expressed genes driving inflammation, and genes supporting B lymphocyte activation. This analysis points out that multiple types of T lymphocytes have to be targeted for therapeutic regeneration of tolerance in arthritis.
- 1 January 2015
- Published by Georg Thieme Verlag KG in Arthritis und Rheuma
- Vol. 35 (04) , 238-246
Hauterscheinungen bei Vaskulitiden
Zusammenfassung: Eine Vaskulitis stellt eine inflammatorische Erkankung der Gefäße mit anschließender Schädigung der Gefäßwand dar. Häufig kommt es bei akuten oder chronischen Vaskulitiden zu einem primären Befall der Hautgefäße, die zu entsprechenden sichtbaren klinischen Ausprägungen führen. Zum einen kann dies eine Chance darstellen, die zugrunde liegende Entität rasch zu erfassen und damit weitere nötige zielgerichtete diagnostische Schritte bzw. therapeutische Maßnahmen einzuleiten; zum anderen überlappt das klinische Bild unterschiedlicher Vaskulitiden allerdings häufig, so dass die klare Zuordnung eine klinische Herausforderung darstellen kann. Ziel dieser Arbeit ist es, anhand des spezifischen Gefäßbefallsmusters und der sich daraus ableitenden Histologien Rückschlüsse auf das klinische Erscheinungsbild zu ziehen, um die Zuordnung des Hautbefundes zu einer spezifischen Entität zu erleichtern.
- 1 January 2015
- Published by Georg Thieme Verlag KG in Arthritis und Rheuma
- Vol. 35 (04) , 238-246
Hauterscheinungen bei Vaskulitiden
Zusammenfassung: Eine Vaskulitis stellt eine inflammatorische Erkankung der Gefäße mit anschließender Schädigung der Gefäßwand dar. Häufig kommt es bei akuten oder chronischen Vaskulitiden zu einem primären Befall der Hautgefäße, die zu entsprechenden sichtbaren klinischen Ausprägungen führen. Zum einen kann dies eine Chance darstellen, die zugrunde liegende Entität rasch zu erfassen und damit weitere nötige zielgerichtete diagnostische Schritte bzw. therapeutische Maßnahmen einzuleiten; zum anderen überlappt das klinische Bild unterschiedlicher Vaskulitiden allerdings häufig, so dass die klare Zuordnung eine klinische Herausforderung darstellen kann. Ziel dieser Arbeit ist es, anhand des spezifischen Gefäßbefallsmusters und der sich daraus ableitenden Histologien Rückschlüsse auf das klinische Erscheinungsbild zu ziehen, um die Zuordnung des Hautbefundes zu einer spezifischen Entität zu erleichtern.